These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 31100231)

  • 1. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
    Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial
    Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM
    J Nucl Med; 2019 Jul; 60(7):950-954. PubMed ID: 30552200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
    Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Nikitas J; Gafita A; Benz MR; Djaïleb L; Farolfi A; Hotta M; Sonni I; Alano R; Rettig M; Shen J; Armstrong W; Grogan T; Liu S; Czernin J; Calais J
    Sci Rep; 2024 Oct; 14(1):24411. PubMed ID: 39420060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
    Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flare on [
    Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted
    Zukotynski KA; Emmenegger U; Hotte S; Kapoor A; Fu W; Blackford AL; Valliant J; Bénard F; Kim CK; Markowski MC; Eisenberger MA; Antonarakis ES; Pienta KJ; Gorin MA; Lubanovic M; Kim J; Pomper MG; Cho SY; Rowe SP
    J Nucl Med; 2021 Oct; 62(10):1430-1437. PubMed ID: 33608426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
    Küper AT; Kersting D; Telli T; Herrmann K; Rominger A; Afshar-Oromieh A; Lopes L; Karkampouna S; Shi K; Kim M; Hadaschik B; Darr C; Umutlu L; Fendler WP; Seifert R
    Theranostics; 2024; 14(9):3623-3633. PubMed ID: 38948055
    [No Abstract]   [Full Text] [Related]  

  • 12. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of androgen deprivation therapy on
    Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.
    Sheikhbahaei S; Werner RA; Solnes LB; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
    Semin Nucl Med; 2019 Jul; 49(4):255-270. PubMed ID: 31227049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S; Güven O; Karyağar SS; Arici S; Selvi O; Geredeli Ç; Özülker F
    Nucl Med Commun; 2021 Sep; 42(9):1011-1016. PubMed ID: 33958536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer.
    Esen B; Herrmann K; Bavbek S; Kordan Y; Tilki D; Esen T
    Eur Urol Focus; 2023 Jul; 9(4):596-605. PubMed ID: 36842919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.